Ancient enemy, modern imperative - A time for greater action against tuberculosis

Health

Ancient enemy, modern imperative - A time for greater action against tuberculosis

June 30, 2014

Europe

Martin Koehring
Martin Koehring

June 30, 2014

Europe

Martin Koehring
Martin Koehring
Martin Koehring

Senior Manager for Sustainability, Climate Change and Natural Resources & Head of the World Ocean Initiative

Martin Koehring is senior manager for sustainability, climate change and natural resources at (part of The Economist Group). He leads Economist Impact's sustainability-related policy and thought leadership projects in the EMEA region. He is also the head of the, inspiring bold thinking, new partnerships and the most effective action to build a sustainable ocean economy.

He is a member of the Advisory Committee for the UN Environment Programme’s Global Environment Outlook for Business and is a faculty member in the Food & Sustainability Certificate Program provided by the European Institute for Innovation and Sustainability.

His previous roles at The Economist Group, where he has been since 2011, include managing editor, global health lead and Europe editor at The Economist Intelligence Unit.

He earned a bachelor of economic and social studies in international relations from Aberystwyth University and a master’s degree in diplomacy and international relations from the College of Europe.

Read more from Martin Koehring
Contact
H

How can health systems tackle tuberculosis?

Tuberculosis (TB) is the second-biggest single infectious killer—after HIV/AIDS—on earth, causing the death of 1.3m people in 2012. Ancient enemy, modern imperative: A time for greater action against tuberculosis, a new Economist Intelligence Unit report supported by Janssen, shows that TB efforts to date have often suffered from a lack of compelling ambition and interest. What are the barriers to fighting the disease?

Economist Impact is a part of the Economist Group.
Occasionally, we would like to keep you informed about our newly-released content, events, our best subscription offers, and other new product offerings from The Economist Group.

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here.

More from this series

Health

article

Romania and tuberculosis

Romania’s current tuberculosis (TB) problems illustrate the consequence of what happens when the challenges of such a

Read more
Health

article

Tuberculosis in the Baltics

After the Baltic states (Estonia, Latvia and Lithuania) found independence in the early 1990’s, as with other

Read more
Health

article

Tuberculosis control in Poland

"The numbers indicate that they have their act together," says Dr Neil Schluger, chief scientific officer at the World

Read more

Related content

13722

Health

Value-based healthcare in Sweden: Reaching the next level

The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.

These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit. 

This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.

Read more

Health

Breast cancer patients and survivors in the Asia-Pacific workforce

With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?

This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.
Read more

Health

The Cost of Silence

Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.

As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.

To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.

Download the report to learn more.

Read more

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week

Copyright © The Economist Newspaper Limited 2024. All rights reserved.